BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 10499623)

  • 21. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer.
    Yamaguchi K; Chijiiwa K; Torato N; Kinoshita M; Tanaka M
    Am J Gastroenterol; 2000 Aug; 95(8):1939-45. PubMed ID: 10950039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Havrilesky L; Darcy kM; Hamdan H; Priore RL; Leon J; Bell J; Berchuck A;
    J Clin Oncol; 2003 Oct; 21(20):3814-25. PubMed ID: 14551300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apoptosis loss and bcl-2 expression: key determinants of lymph node metastases in T1 breast cancer.
    Sierra A; Castellsagué X; Tórtola S; Escobedo A; Lloveras B; Peinado MA; Moreno A; Fabra A
    Clin Cancer Res; 1996 Nov; 2(11):1887-94. PubMed ID: 9816145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
    Buller RE; Lallas TA; Shahin MS; Sood AK; Hatterman-Zogg M; Anderson B; Sorosky JI; Kirby PA
    Clin Cancer Res; 2001 Apr; 7(4):831-8. PubMed ID: 11309330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.
    Liu FS; Kohler MF; Marks JR; Bast RC; Boyd J; Berchuck A
    Obstet Gynecol; 1994 Jan; 83(1):118-24. PubMed ID: 8272291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx.
    Spector JG; Sessions DG; Haughey BH; Chao KS; Simpson J; El Mofty S; Perez CA
    Laryngoscope; 2001 Jun; 111(6):1079-87. PubMed ID: 11404625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.
    Kohler MF; Kerns BJ; Humphrey PA; Marks JR; Bast RC; Berchuck A
    Obstet Gynecol; 1993 May; 81(5 ( Pt 1)):643-50. PubMed ID: 8469448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increase in the frequency of p16INK4 gene inactivation by hypermethylation in lung cancer during the process of metastasis and its relation to the status of p53.
    Seike M; Gemma A; Hosoya Y; Hemmi S; Taniguchi Y; Fukuda Y; Yamanaka N; Kudoh S
    Clin Cancer Res; 2000 Nov; 6(11):4307-13. PubMed ID: 11106248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma.
    Tiguert R; Bianco FJ; Oskanian P; Li Y; Grignon DJ; Wood DP; Pontes JE; Sarkar FH
    J Urol; 2001 Dec; 166(6):2155-60. PubMed ID: 11696726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
    Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
    Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection.
    Yang Y; Forslund A; Remotti H; Lönnroth C; Andersson M; Brevinge H; Svanberg E; Lindnér P; Hafström L; Naredi P; Lundholm K
    Cancer; 2001 Feb; 91(4):727-36. PubMed ID: 11241240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
    Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC
    Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
    Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
    Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p21 expression predicts outcome in p53-null ovarian carcinoma.
    Rose SL; Goodheart MJ; DeYoung BR; Smith BJ; Buller RE
    Clin Cancer Res; 2003 Mar; 9(3):1028-32. PubMed ID: 12631602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases.
    Stapleton AM; Timme TL; Gousse AE; Li QF; Tobon AA; Kattan MW; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
    Clin Cancer Res; 1997 Aug; 3(8):1389-97. PubMed ID: 9815823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [P53-status in primary ovarian carcinomas, ovarian metastases of neoplasms in other sites and benign ovarian tumors: predictive value in comparison to histopathological parameters].
    Casper F; Weikel W; Schaffrath M; Kuner RP; Hoffmann G; Pollow B; Pollow K
    Zentralbl Gynakol; 2000; 122(3):153-9. PubMed ID: 10756599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
    Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
    Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma.
    Kim JW; Cho YH; Kwon DJ; Kim TE; Park TC; Lee JM; Namkoong SE
    Gynecol Oncol; 1995 May; 57(2):199-204. PubMed ID: 7729734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.